Malaysia
Search
Sign In
Change Password
Points
Sign Out
Rheumatology
Top Medical News
Adherence to the Mediterranean diet (MD) may reduce the risk of rheumatoid arthritis (RA) in women who are ever-smokers, according to the French E3N-EPIC* study.
Patellofemoral osteoarthritis (PFOA) symptoms are associated with higher odds of depressive symptoms, catastrophizing, and temporal summation (TS), regardless of magnetic resonance imaging (MRI) PFOA status, reports a recent study. In addition, males with PFOA symptoms without MRI PFOA exhibit local hyperalgesia.
Individuals with high fasting glucose levels have a decreased risk of developing osteoporosis, a study suggests.
Serum urate (SU)-associated genetic variants have a robust impact on gout risk among individuals taking diuretics, with an effect comparable to those not taking the said agent, according to a recent study.
Treatment with rituximab (RTX) results in better 2-year progression-free survival (PFS) compared to cyclophosphamide (CYC) despite similar PFS at 6 months in patients with antisynthetase syndrome (AS)-related interstitial lung disease (ILD), a study has shown.
In patients with early rheumatoid arthritis (RA), vitamin D deficiency is associated with more active and severe disease at baseline and is a predictor of disability and radiographic progression, suggests a study.
For rheumatoid arthritis (RA) patients initiating a new treatment, contactless monitoring via a smartphone application cuts down on office visits while keeping up tight control of disease activity, which in turn boosts general well-being, as shown in a study.
Conference Reports
The US FDA has given secukinumab the greenlight for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA), following its success in the phase III PREVENT trial, the largest ever for a biologic in nr-axSpa.
The IL-1 receptor antagonist anakinra – a drug for rheumatoid arthritis – demonstrated potential in treating gout, as it reduced gout pain and flares to similar degrees as triamcinolone, results of the ANAGO* study have shown.
The investigational interleukin (IL)-6 inhibitor olokizumab is effective in improving symptoms and physical function of patients with moderate-to-severe rheumatoid arthritis (RA) who are inadequately controlled with methotrexate (MTX), according to the CREDO-1 study presented at the EULAR 2020 Virtual Meeting.
Use of the monoclonal antibody ixekizumab led to improvements in symptoms, work productivity, and overall functioning and health in patients with nonradiographic axial spondyloarthritis (nr-axSpA), subgroup results of the phase III COAST-X trial have shown.
The type I interferon receptor antibody anifrolumab reduced disease activity and flares in patients with moderate-to-severe active systemic lupus erythematosus (SLE), results of the TULIP-1 and TULIP-2 trials have shown.
Treatment with tanezumab, a monoclonal antibody against nerve growth factor, significantly reduces pain intensity and improves daily function in patients with chronic low back pain, according to a trial presented at EULAR 2020.
The anti-interleukin 17A antibody netakimab reduces disease activity and skin manifestations in patients with active psoriatic arthritis (PsA), consequently improving patient-reported outcomes (PROs), analyses of the phase III PATERA trial have shown.